Is AI transforming the oncology field?
This issue of our newsletter is supported by Cryoport Systems.
The promise of AI in biotech and, more specifically, in oncology, is vast.?The integration of AI into oncology is not just about speeding up processes – it’s about changing how we understand, detect, and treat one of the world’s most complex diseases.
And the next decade is likely to bring even more transformative changes in this area.?So, how exactly is AI evolving cancer detection and drug discovery and development? And what challenges remain for the use of AI in oncology??
This week, we took a comprehensive look at how AI is transforming cancer care today.?
To find out more, read the full article: “The AI boom in cancer: Game-changer or just hype? ”
A MESSAGE FROM OUR SPONSOR CRYOPORT SYSTEMS
Global experts in temperature-controlled supply chain management for critical biomaterials
Cryoport Systems' temperature-controlled supply chain solutions, including logistics, biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling the Outcome? for patients around the world.
?? Learn more
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
Janus Kinase (JAK) inhibitors are a popular class of drugs in the biopharma industry, as several have been approved to treat inflammatory diseases and cancer, and regularly bring in billions of dollars in yearly revenue for pharma giants like Pfizer and AbbVie. They work by inhibiting the activity of one or more of the JAK family of enzymes, which all play a key role in cytokine signaling and are linked to both inflammatory diseases and cancer.
A good biotech entrepreneur is able to cope with change and failure and has proven their expertise in hitting milestones, be it in the lab or when raising funds to bring their technologies and therapies to market. We reached out to venture capitalists to nominate prominent founders and entrepreneurs in the biotech industry who are committed to bringing potentially life-changing treatments to market and have come a long way in doing so.
Can we reverse the aging process? That is what Shift Bioscience is aiming for through gene discovery, AI-driven simulations, and cellular reprogramming. The Cambridge-based company raised $16 million in a seed funding round that will accelerate the development of its AI platform, which predicts gene-based interventions capable of safely rejuvenating human cells.
Nanotechnology, which is the manipulation of molecules on an atomic scale, has been implemented by companies in medicine, with numerous applications in drug discovery, tissue engineering, imaging, and diagnostics. As techniques and tools to exploit nanotechnology in the field of healthcare progress, we take a look at eight nanotechnology companies that we think you should know about.
Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. This week, we had a conversation with Michael Parini, CEO of Spur Therapeutics, about the future of gene therapy.
The market for 3D cell models is projected to skyrocket from $1.42 billion to $5.29 billion by 2032, fueled by their pivotal role in advancing disease research and drug development. Our Sartorius-sponsored report explores the groundbreaking impact of 3D organoids, highlighting their current impact on research across key therapeutic areas and providing a detailed analysis and discussion of their benefits, challenges, and future directions.
Antibody-drug conjugates (ADCs) represent an innovative class of potent anti-cancer agents. They combine the specificity of a monoclonal antibody with the potency of a cytotoxic drug, enabling targeted killing of cancer cells with lower off-target effects. Over time, ADCs have evolved to high complexity and variability, posing increasing challenges in product characterization and quality control that must be addressed to advance their use in the clinic.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.